CN112569133A - 紧致抗皱精华霜及其制备方法 - Google Patents
紧致抗皱精华霜及其制备方法 Download PDFInfo
- Publication number
- CN112569133A CN112569133A CN202011640927.3A CN202011640927A CN112569133A CN 112569133 A CN112569133 A CN 112569133A CN 202011640927 A CN202011640927 A CN 202011640927A CN 112569133 A CN112569133 A CN 112569133A
- Authority
- CN
- China
- Prior art keywords
- parts
- skin
- essence cream
- active ingredient
- wrinkle essence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 39
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 25
- -1 polydimethylsiloxane Polymers 0.000 claims abstract description 18
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 14
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 9
- 102000008186 Collagen Human genes 0.000 claims abstract description 9
- 108010035532 Collagen Proteins 0.000 claims abstract description 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 9
- 229920001436 collagen Polymers 0.000 claims abstract description 9
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 8
- SCVVSSZVLZQUDZ-UHFFFAOYSA-N 3-methyl-2,6-dihydro-1H-pyrimidine-2-carboxylic acid Chemical compound CN1C(NCC=C1)C(=O)O SCVVSSZVLZQUDZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract description 8
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 8
- 229960003237 betaine Drugs 0.000 claims abstract description 8
- 229940036350 bisabolol Drugs 0.000 claims abstract description 8
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 8
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 claims abstract description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 7
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims abstract description 7
- 241001135917 Vitellaria paradoxa Species 0.000 claims abstract description 7
- 229940057910 shea butter Drugs 0.000 claims abstract description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 241000209490 Nymphaea Species 0.000 claims abstract description 4
- 235000016791 Nymphaea odorata subsp odorata Nutrition 0.000 claims abstract description 4
- 229920006037 cross link polymer Polymers 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 3
- 230000003750 conditioning effect Effects 0.000 claims abstract description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 3
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 claims abstract description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-M prolinate Chemical compound [O-]C(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-M 0.000 claims abstract description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims abstract description 3
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 31
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
- 230000001804 emulsifying effect Effects 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 229960005150 glycerol Drugs 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003974 emollient agent Substances 0.000 claims description 6
- 229940031575 hydroxyethyl urea Drugs 0.000 claims description 6
- 229960005323 phenoxyethanol Drugs 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 5
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 5
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 5
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 5
- 229960004063 propylene glycol Drugs 0.000 claims description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 5
- BXCRLBBIZJSWNS-UHFFFAOYSA-N 2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCO BXCRLBBIZJSWNS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 229960000541 cetyl alcohol Drugs 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 claims description 4
- 229940105132 myristate Drugs 0.000 claims description 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 4
- 229940075529 glyceryl stearate Drugs 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 3
- PAEMERHSTIDLSE-VEIQOZLZSA-N (3r,4s,5s,6r)-2-hexadecoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PAEMERHSTIDLSE-VEIQOZLZSA-N 0.000 claims description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000037303 wrinkles Effects 0.000 abstract description 8
- 239000002537 cosmetic Substances 0.000 abstract description 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 64
- 238000012360 testing method Methods 0.000 description 39
- 230000000052 comparative effect Effects 0.000 description 26
- 239000000686 essence Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000001815 facial effect Effects 0.000 description 17
- 230000008859 change Effects 0.000 description 14
- 230000003020 moisturizing effect Effects 0.000 description 12
- 230000003712 anti-aging effect Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 9
- 230000032683 aging Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000005562 fading Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- XOAIXMQPJQVGRV-UHFFFAOYSA-N 1-hexadecanoylpyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N1CCCC1C(O)=O XOAIXMQPJQVGRV-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000195619 Euglena gracilis Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 102000005717 Myeloma Proteins Human genes 0.000 description 1
- 108010045503 Myeloma Proteins Proteins 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VKIJBOMCWLTQBD-UHFFFAOYSA-N benzoic acid N-(2-hydroxyphenyl)propanamide Chemical compound C(C1=CC=CC=C1)(=O)O.C(CC)(=O)NC1=C(C=CC=C1)O VKIJBOMCWLTQBD-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229940108690 glucosyl hesperidin Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940087068 glyceryl caprylate Drugs 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940049290 hydrogenated coco-glycerides Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229940023750 peg-60 glyceryl isostearate Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037070 skin defense Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及化妆品技术领域，公开了一种紧致抗皱精华霜及其制备方法，该精华霜包括质量百分含量为16～29％的皮肤调理剂；皮肤调理剂包括透明质酸钠、氢化卵磷脂、四氢甲基嘧啶羧酸、水解胶原、甜菜碱、二棕榈酰羟脯氨酸、牛油果树果脂、生育酚乙酸酯、活性成分A、活性成分B、活性成分C及红没药醇；活性成分A包括聚二甲基硅氧烷、环五聚二甲基硅氧烷及聚甲基硅倍半氧烷，活性成分B包括环五聚二甲基硅氧烷及聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物，活性成分C包括棕榈酰脯氨酸钠及白睡莲提取物。该精华霜可以起到紧致肌肤、淡化细纹皱纹的显著功效。
Description
技术领域
本发明涉及化妆品技术领域，特别是涉及一种紧致抗皱精华霜及其制备方法。
背景技术
众所周知，肌肤老化分自然老化和环境因素导致的老化，一般25岁以后，女性的皮肤的新陈代谢就会日趋缓慢，角质层会渐渐堆积变厚。除了年龄会影响皮肤状况，由于工作、生活压力导致的体内荷尔蒙的变化，环境的污染，紫外线的辐射，不良的饮食习惯以及不恰当的肌肤保养方式均会影响皮肤健康，导致大量自由基的生成，这些活跃的分子基团会引发一系列自由基反应，造成细胞的损伤甚至死亡，从而使肌肤加速衰老。坚持长期正确使用有效的抗衰紧致护肤品，在一定程度上可以有效延缓皮肤衰老的速度。
目前，市场上宣称抗衰紧致的护肤品品类繁多、质量也良莠不齐，有的产品使用后不但起不到抗衰老的效果，反而带来刺激、瘙痒等肌肤问题，或导致敏感肌肤的出现，有的产品只能对25～35的初老皮肤起到抗衰老的效果，对于 35～55岁的衰老皮肤却功效甚微。
中国专利CN110787074A公开了一种淡化细纹的组合物，由A、B、C、D、 E、F、G、H、I、J、K、L、M组分组成；其中：A组分由水、双丙甘醇、异十六烷、辛酸/癸酸甘油三酯、氢化椰油甘油脂类、丁二醇、丙二醇、甘油、硬脂醇、牛油果树果脂、矿油、聚二甲基硅氧烷、滑石粉、硬脂酸、PEG-60甘油异硬脂酸酯、山嵛醇、葡糖基橙皮苷、1,2-戊二醇、海藻糖、硅石、泛醇、胆甾醇羟基硬A脂酸酯、肌肽、生育酚乙酸酯、尿囊素、苯氧乙醇、鲸蜡醇磷酸酯钾、三乙醇胺、丙烯酸或酯类/C10-30烷醇丙烯酸酯交联聚合物、辛甘醇、EDTA-二钠、透明质酸钠、白藜芦醇、突厥蔷薇花提取物、香精、着色剂CI75470、着色剂CI 15985、着色剂CI 19140、着色剂CI17200组成；B组分由花生醇、山嵛醇、花生醇葡糖苷组成；C组分由二裂酵母发酵产物滤液、辛酰羟肟酸、丙二醇、甘油辛酸酯、苯氧乙醇组成D组分由丁二醇、水解酵母提取物组成；E组分由羟苯基丙酰胺苯甲酸、抗坏血酸棕榈酸酯、丁二醇、1,2-戊二醇组成、F组分由野大豆籽提取物、甘油组成；G组分由细小裸藻多糖、水解胶原组成；H组分由水、棕榈酰寡肽、棕榈酰四肽-7、丁二醇、卡波姆、甘油、聚山梨醇酯-20组成； I组分由水、水解弹性蛋白、柠檬酸、环庚三烯酚酮、聚山梨醇酯-20、辛甘醇、乙基己基甘油、1,2-己二醇组成；J组分由水、棕榈酰五肽-4、甘油、丁二醇、卡波姆、聚山梨醇酯-20组成；K组分由水、神经酰胺3、辛酸/癸酸甘油三酯、胆甾醇、氢化卵磷脂、植物鞘氨醇、硬脂酸、油酸、乳酸组成；L组分由苹果果实细胞培养物提取物、甘油、卵磷脂、黄原胶、苯氧乙醇组成；M组分由水、丁二醇、蜂王浆提取物组成。该组合物具有一定的补水保湿的功效，但是对35～55 岁的衰老皮肤的抗衰老的功效不明显。
因此有必要开发一种使用体验感佳，滋润而不黏腻，温和无刺激的面霜，尤其是对于紧致肌肤、淡化细纹皱纹具有显著效果的紧致抗皱精华霜。
发明内容
本发明的目的是克服现有技术中的不足之处，一方面提供一种紧致抗皱精华霜，主要针对35～55岁的衰老肌肤，可以起到紧致肌肤、淡化细纹皱纹的显著功效；另一方面提供上述紧致抗皱精华霜的制备方法。
本发明的目的是通过以下技术方案来实现的：
一方面，本发明提供了一种紧致抗皱精华霜，包括质量百分含量为16～29％的皮肤调理剂；
其中，所述皮肤调理剂包括透明质酸钠、氢化卵磷脂、四氢甲基嘧啶羧酸、水解胶原、甜菜碱、二棕榈酰羟脯氨酸、牛油果树果脂、生育酚乙酸酯、活性成分A、活性成分B、活性成分C及红没药醇；所述活性成分A包括聚二甲基硅氧烷、环五聚二甲基硅氧烷及聚甲基硅倍半氧烷其中至少一种，所述活性成分B包括环五聚二甲基硅氧烷及聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物其中至少一种，所述活性成分C包括棕榈酰脯氨酸钠及白睡莲提取物其中至少一种。
优选地，所述皮肤调理剂包括以下质量份数的组分：透明质酸钠0.03～0.07 份、氢化卵磷脂0.6～1份、四氢甲基嘧啶羧酸0.05～0.15份、水解胶原0.3～0.7 份、甜菜碱2～4份、二棕榈酰羟脯氨酸0.3～0.7份、牛油果树果脂6～10份、生育酚乙酸酯0.3～0.7份、活性成分A 3～5份、活性成分B 3～5份、活性成分C 0.5～1.5 份及红没药醇0.03～0.07份。
在其中一种实施方式，所述紧致抗皱精华霜还包括质量百分含量为 10～18.3％的保湿剂，所述保湿剂包括丙二醇、甘油、羟乙基脲及乙基己基甘油其中至少一种。优选地，所述保湿剂包括以下质量份数的组分：丙二醇4～8份、甘油4～6份、羟乙基脲2～4份及乙基己基甘油0.1～0.3份。
在其中一种实施方式，所述紧致抗皱精华霜还包括质量百分含量为 5.5～10.5％的润肤剂，所述润肤剂包括氢化聚异丁烯、聚二甲基硅氧烷及环五聚二甲基硅氧其中至少一种。优选地，所述润肤剂包括以下质量份数的组分：氢化聚异丁烯3～5份、聚二甲基硅氧烷0.5～1.5份及环五聚二甲基硅氧烷2～4份。
在其中一种实施方式，所述紧致抗皱精华霜还包括以下质量百分含量的组分：增稠剂0.15～0.35％、螯合剂0.03～0.07％、乳化剂6.3～12.5％、抗氧化剂0～0.07％及PH调节剂0.05～0.15％。
优选地，所述乳化剂包括乳化成分A、鲸蜡硬酯醇、乙二醇棕榈酸酯、甘油硬脂酸酯及聚甘油-10肉豆蔻酸酯其中至少一种，所述乳化成分A包括鲸蜡硬酯醇及鲸蜡硬酯基葡糖苷其中至少一种。优选地，所述乳化剂包括以下质量份数的组分：乳化成分A 2～4份、鲸蜡硬酯醇1.2～3.2份、乙二醇棕榈酸酯2～3份、甘油硬脂酸酯1～2份及聚甘油-10肉豆蔻酸酯0.1～0.3份。
优选地，所述增稠剂包括卡波姆及黄原胶其中至少一种。优选地，所述增稠剂包括以下质量份数的组分：卡波姆0.1～0.2份及黄原胶0.05～0.15份。
优选地，所述螯合剂为EDTA-二钠。
优选地，所述抗氧化剂为丁羟甲苯。
优选地，所述PH调节剂为三乙醇胺。
在其中一种实施方式，所述紧致抗皱精华霜还包括质量百分含量为0～1.6％的防腐剂，所述防腐剂包括羟苯甲酯、羟苯丙酯及苯氧乙醇其中至少一种。优选地，所述防腐剂包括以下质量份数的组分：羟苯甲酯0～0.2份、羟苯丙酯0～0.7 份及苯氧乙醇0～0.7份。
在其中一种实施方式，所述紧致抗皱精华霜还包括质量百分含量为0～0.1％的香精。
四氢甲基嘧啶羧酸又称Ectoin或依克多因，作为一种渗透压补偿性溶质存在于耐盐菌中，在细胞内起到化学递质样作用，对细胞在逆环境中有稳定性的保护作用，也能稳定生物体内酶蛋白的结构，有活肤抗衰的功能；可提供良好的保湿和防晒功能，并有美白皮肤的作用；四氢甲基嘧啶羧酸也可保护中性粒细胞，显示有抗炎作用。
二棕榈酰羟脯氨酸(简称为DPHP)是由天然产物棕榈酸与天然氨基酸羟脯氨酸合成的抗皱、紧肤化妆品原料，羟脯氨酸携带的脂肪基团有效提高了皮肤对羟脯氨酸的亲和吸收能力。DPHP进入皮肤后在脂肪酶的作用下羟脯氨酸得以释放，DPHP能刺激胶原蛋白的重排，收缩胶原纤维，恢复皮肤坚实度，它的活性明显强于维生素C，保护弹性蛋白免受酶的破坏，DPHP比维生素C抑制弹性蛋白酶的活性更强，能促进胶原蛋白合成，清除氧自由基，具有三重紧肤作用，其DPHP速效的抗皱、紧肤、提高皮肤弹性的功效已被大量的科学实验所证明，是一种具有突出效果的抗衰老新原料。同时DPHP还可以增加皮肤中水份含量，良好保湿作用。
另一方面，本发明还提供了上述紧致抗皱精华霜的制备方法，包括以下步骤：将所述皮肤调理剂搅拌均匀。
与现有技术相比，本发明至少具有以下优点：
1、本发明提供的紧致抗皱精华霜通过牛油果树果脂、氢化卵磷脂等油脂类成分，丙二醇、甘油、羟乙基脲等吸湿性成分，透明质酸钠、水解胶原等亲水性成分，及甜菜碱、生育酚乙酸酯、活性成分C、红没药醇等修复性成分之间的相互协同的增效作用，能多方面呵护皮肤，强效密集补水保湿，对35～55岁的衰老皮肤可以起到显著的瞬时补水保湿的功效；同时构建肌肤防御堡垒，强健肌底；再通过四氢甲基嘧啶羧酸、二棕榈酰羟脯氨酸等强效的抗衰老成分，复配活性成分A及活性成分B，通过活性成分A及活性成分B的抗紫外线作用，来抵御由紫外线引起的皮肤衰老，从而增效抗皱抗衰老的功能，能多维抗老，重拾弹力改善皮肤松弛；同时起到增稠作用，可以起到减少增稠剂用量的作用，而且质地比油脂类成分更清爽轻薄，可以降低精华霜的油腻感；后通过棕榈酰脯氨酸钠及白睡莲提取物可以减少由于炎症(紫外线、刺激、粉刺)和衰老引起的色素沉着，起到美白祛斑的功效；并且复配甜菜碱、生育酚乙酸酯、红没药醇等成分，还可以帮助皮肤抵抗外界刺激，缓解热敏引起的疼痛，降低表皮温度，达到抗过敏舒缓的效果，有效修复皮肤敏感或皮肤炎症。
2、本发明提供的紧致抗皱精华霜的保湿剂选用了价格非常低廉的丙二醇及乙基己基甘油，乙基己基甘油除了具有补水保湿的功效，还具有抑菌功效，通过降低微生物细胞壁表面张力，降低细菌的活性，可以增效丙二醇的抗菌作用，可以增效防腐剂，通过与EDTA-二钠复配，更有利于防腐剂的增效作用，减少防腐剂的用量，增加产品的安全性。而丙二醇可以增加护肤品质地的清爽度，渗透性强，能帮助其他成分在皮肤表面涂开并渗入；但是作为保湿剂时抓水率不高，通过复配甘油及羟乙基脲，可以提高整个体系的抓水率，提高其补水保湿功效。
3、本发明提供的紧致抗皱精华霜的乳化剂选用了乳化成分A、鲸蜡硬酯醇、乙二醇棕榈酸酯、甘油硬脂酸酯及聚甘油-10肉豆蔻酸酯，这些原料具有很高的安全性及温和性，并且在特定的比例范围内，可以发挥出良好的乳化效果，大大提高紧致抗皱精华霜的稳定性；同时通过复配具有乳化作用的氢化卵磷脂，可以增效乳化作用，减少乳化剂的用量；并且通过复配甜菜碱、生育酚乙酸酯、活性成分C、红没药醇等成分，可以有效降低乳化剂对衰老皮肤的刺激性。
4、本发明提供的紧致抗皱精华霜通过皮肤调理剂、保湿剂、增稠剂、螯合剂、抗氧化剂、乳化剂、PH调节剂、防腐剂等组分的相互协同增效作用下，对 35～55岁的衰老皮肤具有瞬时补水保湿的功效，在强效密集补水保湿的同时，还可以抗敏舒缓，强健肌底，提高皮肤屏障，美白祛斑，紧致肌肤，抗皱抗衰老，淡化细纹皱纹；并且成分安全温和无刺激，使用体验感佳，滋润而不黏腻，成本低，保质期长。
附图说明
为了更清楚地说明本发明实施例的技术方案，下面将对实施例中所需要使用的附图作简单地介绍，应当理解，以下附图仅示出了本发明的某些实施例，因此不应被看作是对范围的限定，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他相关的附图。
图1为实施例1一名受试者在不同的时间点眼下区域细纹的变化。
具体实施方式
需要说明的是，本发明可以以许多不同的形式来实现，并不限于本文所描述的实施方式。相反地，提供这些实施方式的目的是使对本发明的公开内容理解的更加透彻全面。
除非另有定义，本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文中在本发明的说明书中所使用的术语只是为了描述具体的实施方式的目的，不是旨在于限制本发明。本文所使用的术语“及/或”包括一个或多个相关的所列项目的任意的和所有的组合。
实施例1～4的紧致抗皱精华霜，包括质量百分含量为如表1所示组分。
表1.实施例1～4组分表
将表1中的配方按照以下步骤进行制备：
1：将A分相加入乳化锅中，以20～40r/min搅拌，再将提前分别混合好的 A1分相和A3分相加入乳化锅中，升温至80～85度，保温15～25min，再以20～40HZ 频率均质2～4min，再加入A2分相，搅拌降温并抽真空3～5min；
2：将B分相于油锅中80～90度溶解完全，乳化前1～3min加入B1分相，均质1～3min，搅拌均匀；
3：将步骤2得到的混合物加入乳化锅中，以30～40HZ的频率均质2～4min，搅拌均匀；
4：将步骤3得到的混合物以20～40r/min速度真空搅拌降温到65～70度，加入C分相，搅拌均匀；
5：将步骤4得到的混合物以20～40r/min速度降温到45～50度，加入D分相、 E分相和F分相，搅拌均匀；
6：将步骤5得到的混合物以20～40r/min速度继续搅拌降温到35～40度，加入G分相，搅拌均匀；
7：待品控检验合格后，出料。
对比例1
中国专利CN110787074A公开的实施例1的制备得到的淡化细纹的组合物。
测试实验：1、皮肤含水量测试—补水保湿
受试者要求：选择35～55岁敏感皮肤的女性，按照测试品的种类分组。n代表每组人数。
数据统计：数据使用SPSS进行统计，对测试数据进行正态分布检验，若测试数据为正态分布，则采用t检验方法进行统计分析；若测试数据为非正态分布，则采用秩和检验方法进行统计分析，统计方法均采用双尾检验，检验水准α＝0.05。
测试方法：左右脸随机对照，双盲测试；分别取约珍珠大小的实施例1～4 及对比例1的测试品于双手指腹温热数秒，均匀涂抹于面部，然后采用皮肤水分测试仪(德国CKCorneometer CM 825)在使用前、30min、1h、1.5h、2h测试左右面部测试区域的皮肤含水量，实施例1及对比例1的测试结果如表2所示。实施例2～4的测试结果与实施例1的测试结果相近，实施例1的皮肤含水量的增加量最高，为最佳实施例。
表2受试者在不同的时间点面部测试区域角质层水分含量
皮肤水分测定仪Corneometer CM 825用于检测皮肤角质层水分含量，皮肤角质层水分含量测量值越高，说明皮肤角质层水分含量越高。
由表2数据可见，使用实施例1的测试品在使用30min面部皮肤角质层水分含量变化值与使用前皮肤水分含量变化值的数据差异，不具有统计学意义 (P>0.05)。使用实施例1的测试品在使用1h、1.5h、2h面部皮肤角质层水分含量变化值与使用前皮肤水分含量变化值的数据差异，均具有统计学意义 (P<0.05)，整体皮肤含水量成上升趋势。对比例1在使用30min、1h面部皮肤角质层水分含量变化值与使用前皮肤水分含量变化值的数据差异，不具有统计学意义(P>0.05)，对比例1在使用1.5h、2h面部皮肤角质层水分含量变化值与使用前皮肤水分含量变化值的数据差异，具有统计学意义(P<0.05)。同时，实施例1和对比例1两组的测定值与初始值的差值在使用30min、1h、1.5h进行比较，数据不具有显著性差异(P>0.05)，实施例1和对比例1两组的测定值与初始值的差值在使用2h进行比较，数据具有显著性差异(P<0.05)。实施例1 在15min、30min、1h、1.5h、2h的测定值与初始值的差值与对比例1相比，差值更大，说明实施例1的补水效果更好。
表2数据表明，相比于对比例1，本发明提供的紧致抗皱精华霜能够明显提高衰老皮肤角质层水分含量，对衰老皮肤的补水保湿的效果更显著。
2、经皮水分流失测试—皮肤屏障
采用经皮水分流失测试探头(德国CKTewameter TM Hex)检测左右脸颊颧骨皮肤在使用前，30min、1h、1.5h、2h的经皮水分流失率(TEWL)。实施例 1及对比例1的测试结果如表3所示。实施例2～4的测试结果与实施例1的测试结果相近，实施例1的皮肤水分流失率更低，为最佳实施例。
表3受试者在不同的时间点面部测试区域TEWL值的变化
经皮水分流失测试探头(德国CKTewameter TM Hex)检测皮肤经皮水分流失率，皮肤经皮水分流失率越低，表明皮肤屏障功能越好。由表3数据可见，使用实施例1的测试品在使用30min、1h、1.5h、2h TEWL值变化值与使用前 TEWL值变化值的数据差异，均具有统计学意义(P<0.05)，对比例1在使用 30min、1h、1.5h面部皮肤角质层TEWL值变化值与使用前皮肤TEWL值变化值的数据差异，具有统计学意义(P<0.05)，对比例1在使用2h面部皮肤TEWL变化值与使用前皮肤TEWL变化值的数据差异，不具有统计学意义(P>0.05)。同时，实施例1和对比例1两组的测定值与初始值的差值在使用30min、1h进行比较，数据不具有显著性差异(P>0.05)，实施例1和对比例1两组的测定值与初始值的差值在使用1.5h、2h进行比较，数据具有显著性差异(P<0.05)。
表3数据表明，相比于对比例1，本发明提供的紧致抗皱精华霜能够明显降低衰老皮肤经皮水分流失率，提高皮肤屏障的效果更显著。
3、面部图像分析—淡化细纹
3.1眼下细纹测试
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件，选取受试者眼睛下方进行眼下细纹面积计算。实施例1及对比例1的测试结果如表4所示。实施例2～4的测试结果与实施例1的测试结果相近，实施例1的眼下细纹面积减少率最高，为最佳实施例。
图1为实施例1三名受试者在不同的时间点眼下区域细纹的变化。
表4受试者在不同的时间点眼下细纹面积变化
表4数据表明，使用实施例1即时，眼下细纹面积与使用前测试值比较，不具有统计学意义(P>0.05)，使用实施例1 30分钟、1小时、1.5小时、2小时，眼下细纹面积与使用前测试值比较，均具有统计学意义(P<0.05)。使用对比例1即时、30min、1h、2h，眼下细纹面积与使用前测试值比较，不具有统计学意义(P>0.05)，使用对比例1 1.5小时，眼下细纹面积与使用前测试值比较，具有统计学意义(P<0.05)。同时，实施例1和对比例1两组的测定值与初始值的差值在即时、1小时、1.5小时进行比较，数据不具有显著性差异(P>0.05)，实施例1和对比例1两组的测定值与初始值的差值在使用30分钟、2小时进行比较，数据具有显著性差异(P<0.05)。
相比于对比例1，本发明提供的紧致抗皱精华霜能够明显减少衰老皮肤的眼下细纹面积，对衰老皮肤的淡化细纹的效果更显著。同时从图1可看出，在使用2h后，实施例1受试者的眼下细纹明显减少，皮肤更加平整，可见本发明提供的紧致抗皱精华霜能够在短时间(2h)内有效改善衰老皮肤的眼下细纹问题。
3.2面部纹理测试
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件，选取受试者左右脸颊进行面部纹理的计算。实施例1及对比例1的测试结果如表4所示。实施例2～4的测试结果与实施例1的测试结果相近，实施例1的面部纹理值减少率最高，为最佳实施例。
表5受试者在不同的时间点面部纹理值变化
表5数据表明，使用实施例1即时和1.5小时，面部纹理值与使用前测试值比较，不具有统计学意义(P>0.05)，使用实施例1 30分钟、1小时、2小时，面部纹理值与使用前测试值比较，均具有统计学意义(P<0.05)。使用对比例1 即时、1.5小时，面部纹理值与使用前测试值比较，不具有统计学意义(P>0.05)，使用对比例1 30分钟、1小时、2小时，面部纹理值与使用前测试值比较，具有统计学意义(P<0.05)。同时，实施例1和对比例1两组的测定值与初始值的差值在30分钟进行比较，数据不具有显著性差异(P>0.05)，实施例1和对比例 1两组的测定值与初始值的差值在使用即时、1小时、1.5小时、2小时进行比较，数据具有显著性差异(P<0.05)。
表5数据表明，相比于对比例1，本发明提供的紧致抗皱精华霜能够明显减少衰老皮肤的面部细纹面积，对衰老皮肤的淡化细纹的效果更显著。
皮肤不良方应：使用测试品期间，0例受试者出现局部红斑、丘疹、风团、水肿或全身的皮肤不良方应。
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。
Claims (10)
1.一种紧致抗皱精华霜，其特征在于，包括质量百分含量为16～29％的皮肤调理剂；
其中，所述皮肤调理剂包括透明质酸钠、氢化卵磷脂、四氢甲基嘧啶羧酸、水解胶原、甜菜碱、二棕榈酰羟脯氨酸、牛油果树果脂、生育酚乙酸酯、活性成分A、活性成分B、活性成分C及红没药醇；所述活性成分A包括聚二甲基硅氧烷、环五聚二甲基硅氧烷及聚甲基硅倍半氧烷其中至少一种，所述活性成分B包括环五聚二甲基硅氧烷及聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物其中至少一种，所述活性成分C包括棕榈酰脯氨酸钠及白睡莲提取物其中至少一种。
2.根据权利要求1所述的紧致抗皱精华霜，其特征在于，所述皮肤调理剂包括以下质量份数的组分：透明质酸钠0.03～0.07份、氢化卵磷脂0.6～1份、四氢甲基嘧啶羧酸0.05～0.15份、水解胶原0.3～0.7份、甜菜碱2～4份、二棕榈酰羟脯氨酸0.3～0.7份、牛油果树果脂6～10份、生育酚乙酸酯0.3～0.7份、活性成分A 3～5份、活性成分B 3～5份、活性成分C0.5～1.5份及红没药醇0.03～0.07份。
3.根据权利要求1所述的紧致抗皱精华霜，其特征在于，还包括质量百分含量为10～18.3％的保湿剂，所述保湿剂包括丙二醇、甘油、羟乙基脲及乙基己基甘油其中至少一种。
4.根据权利要求1所述的紧致抗皱精华霜，其特征在于，所述保湿剂包括以下质量份数的组分：丙二醇4～8份、甘油4～6份、羟乙基脲2～4份及乙基己基甘油0.1～0.3份。
5.根据权利要求1所述的紧致抗皱精华霜，其特征在于，还包括质量百分含量为5.5～10.5％的润肤剂，所述润肤剂包括氢化聚异丁烯、聚二甲基硅氧烷及环五聚二甲基硅氧其中至少一种。
6.根据权利要求1所述的紧致抗皱精华霜，其特征在于，所述润肤剂包括以下质量份数的组分：氢化聚异丁烯3～5份、聚二甲基硅氧烷0.5～1.5份及环五聚二甲基硅氧烷2～4份。
7.根据权利要求1所述的紧致抗皱精华霜，其特征在于，还包括以下质量百分含量的组分：增稠剂0.15～0.35％、螯合剂0.03～0.07％、乳化剂6.3～12.5％、抗氧化剂0～0.07％及PH调节剂0.05～0.15％。
8.根据权利要求1所述的紧致抗皱精华霜，其特征在于，所述乳化剂包括乳化成分A、鲸蜡硬酯醇、乙二醇棕榈酸酯、甘油硬脂酸酯及聚甘油-10肉豆蔻酸酯其中至少一种，所述乳化成分A包括鲸蜡硬酯醇及鲸蜡硬酯基葡糖苷其中至少一种。
9.根据权利要求1所述的紧致抗皱精华霜，其特征在于，还包括质量百分含量为0～1.6％的防腐剂，所述防腐剂包括羟苯甲酯、羟苯丙酯及苯氧乙醇其中至少一种。
10.根据权利要求1～9任一项所述的一种紧致抗皱精华霜的制备方法，其特征在于，包括以下步骤：将所述皮肤调理剂搅拌均匀。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011640927.3A CN112569133A (zh) | 2020-12-31 | 2020-12-31 | 紧致抗皱精华霜及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011640927.3A CN112569133A (zh) | 2020-12-31 | 2020-12-31 | 紧致抗皱精华霜及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112569133A true CN112569133A (zh) | 2021-03-30 |
Family
ID=75144510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011640927.3A Pending CN112569133A (zh) | 2020-12-31 | 2020-12-31 | 紧致抗皱精华霜及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112569133A (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197785A (zh) * | 2021-06-22 | 2021-08-03 | 杭州友丽医疗科技(集团)有限公司 | 一种抗皱祛红再生组合物、精华液及其制备方法 |
| CN113456507A (zh) * | 2021-07-02 | 2021-10-01 | 上海美莲妮生物科技有限公司 | 一种滋润保湿精华乳及其制备方法 |
| CN114209607A (zh) * | 2022-01-11 | 2022-03-22 | 广东芭薇生物科技股份有限公司 | 一种应用二棕榈酰羟脯氨酸的方法及组合物 |
| CN114224749A (zh) * | 2021-12-31 | 2022-03-25 | 浙江英树生物科技有限公司 | 一种面膜及其制备方法 |
| CN114533614A (zh) * | 2022-02-24 | 2022-05-27 | 武汉百思凯瑞生物科技有限公司 | 一种美白活性肽纳米组合物及其制备方法和应用 |
| CN116019733A (zh) * | 2022-12-26 | 2023-04-28 | 广东康容实业有限公司 | 一种超活南珠多肽母液修复抗衰组合物及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106726999A (zh) * | 2016-12-29 | 2017-05-31 | 重庆领道科技有限公司 | 一种护肤组合物和眼霜 |
| CN110123717A (zh) * | 2019-06-06 | 2019-08-16 | 广州市裕朝化妆品有限公司 | 一种用于修复皮肤屏障的护肤霜 |
| CN110236964A (zh) * | 2019-05-24 | 2019-09-17 | 广州维真渼生物科技有限公司 | 肌活焕白霜及其制备方法 |
| CN111450024A (zh) * | 2020-05-12 | 2020-07-28 | 广州怡嘉生物科技有限公司 | 一种精华霜 |
| CN111632000A (zh) * | 2020-06-24 | 2020-09-08 | 广州市美夫兰化妆品有限公司 | 一种保湿抗皱精华露及其制备方法 |
-
2020
- 2020-12-31 CN CN202011640927.3A patent/CN112569133A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106726999A (zh) * | 2016-12-29 | 2017-05-31 | 重庆领道科技有限公司 | 一种护肤组合物和眼霜 |
| CN110236964A (zh) * | 2019-05-24 | 2019-09-17 | 广州维真渼生物科技有限公司 | 肌活焕白霜及其制备方法 |
| CN110123717A (zh) * | 2019-06-06 | 2019-08-16 | 广州市裕朝化妆品有限公司 | 一种用于修复皮肤屏障的护肤霜 |
| CN111450024A (zh) * | 2020-05-12 | 2020-07-28 | 广州怡嘉生物科技有限公司 | 一种精华霜 |
| CN111632000A (zh) * | 2020-06-24 | 2020-09-08 | 广州市美夫兰化妆品有限公司 | 一种保湿抗皱精华露及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 广州怡嘉生物科技有限公司: "ME时代白睡莲修护精华霜", 《国产非特殊化妆品备案平台，网址：HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=2020113011201682ZVA&NID=2020113011201682ZVA 》 * |
| 广州生生生物科技有限公司: "纪薇兰臻皙年华赋颜精华霜", 《国产非特殊化妆品备案平台，网址：HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20201103085420T0XGI&NID=20201103085420T0XGI 》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113197785A (zh) * | 2021-06-22 | 2021-08-03 | 杭州友丽医疗科技(集团)有限公司 | 一种抗皱祛红再生组合物、精华液及其制备方法 |
| CN113456507A (zh) * | 2021-07-02 | 2021-10-01 | 上海美莲妮生物科技有限公司 | 一种滋润保湿精华乳及其制备方法 |
| CN114224749A (zh) * | 2021-12-31 | 2022-03-25 | 浙江英树生物科技有限公司 | 一种面膜及其制备方法 |
| CN114224749B (zh) * | 2021-12-31 | 2024-01-02 | 浙江英树生物科技有限公司 | 一种面膜及其制备方法 |
| CN114209607A (zh) * | 2022-01-11 | 2022-03-22 | 广东芭薇生物科技股份有限公司 | 一种应用二棕榈酰羟脯氨酸的方法及组合物 |
| CN114533614A (zh) * | 2022-02-24 | 2022-05-27 | 武汉百思凯瑞生物科技有限公司 | 一种美白活性肽纳米组合物及其制备方法和应用 |
| CN114533614B (zh) * | 2022-02-24 | 2023-09-01 | 武汉百思凯瑞生物科技有限公司 | 一种美白活性肽纳米组合物及其制备方法和应用 |
| CN116019733A (zh) * | 2022-12-26 | 2023-04-28 | 广东康容实业有限公司 | 一种超活南珠多肽母液修复抗衰组合物及其应用 |
| CN116019733B (zh) * | 2022-12-26 | 2024-02-20 | 广东康容实业有限公司 | 一种超活南珠多肽母液修复抗衰组合物及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112569133A (zh) | 紧致抗皱精华霜及其制备方法 | |
| US11833242B2 (en) | Skin care formulations | |
| US20210121379A1 (en) | Composition comprising at least two fatty acid esters of (poly)glycerol, and use thereof in cosmetics | |
| CN111297712B (zh) | 一种面霜组合物及其制备方法 | |
| CN110897995A (zh) | 一种美白膏霜及其制备方法 | |
| CN111956591A (zh) | 一种抗敏舒缓和改善肤色的化妆品组合物及其制备方法 | |
| CN112641670A (zh) | 保湿精华乳及其制备方法 | |
| CN112516022B (zh) | 一种防晒露及其制备方法 | |
| KR20180109329A (ko) | 보습 복합물을 함유하는 피부 보습용 화장료 조성물 | |
| WO2020033450A1 (en) | Wrinkle reducing compositions and methods | |
| US20180360712A1 (en) | Cosmetic composition and use thereof | |
| CN112754963A (zh) | 紧致抗皱护肤品的使用方法 | |
| US20220378690A1 (en) | Compositions and methods for treating skin | |
| US20030031688A1 (en) | Cosmetic composition with improved skin moisturizing properties | |
| CN110787074A (zh) | 一种淡化细纹的组合物 | |
| CN112353705B (zh) | 化妆品组合物及其制备方法和具有祛皱、延缓衰老功效的化妆品 | |
| CN113081942A (zh) | 一种含有苹果干细胞的多维水合霜 | |
| CN114288201B (zh) | 一种祛眼袋、淡化黑眼圈的组合物及其制备方法和应用 | |
| CN116637042A (zh) | 一种祛皱抗衰护肤品及其制备方法和应用 | |
| CN114159333B (zh) | 一种肌底液及其制备方法 | |
| JP7305161B2 (ja) | 皮膚化粧料 | |
| CN112656728A (zh) | 抗敏舒缓液及其制备方法 | |
| CN115721596B (zh) | 一种修复抗皱美颜乳 | |
| CN115813832B (zh) | 一种具有改善眼部轮廓的组合物、眼霜及其制备方法和应用 | |
| CN114712277B (zh) | 一种保湿修复组合物和化妆品及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210330 |